HighTower Advisors’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

HighTower Advisors’s Portfolio NBSE Stock Details NBSE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-43	Closed	-$3K	–	2400
2018 Q3	$3K	Hold	43	–	–	﹤0.01%	2241
2018 Q2	$3K	Hold	43	–	–	﹤0.01%	2193
2018 Q1	$3K	Sell	43 -25	-37%	-$3.72K	﹤0.01%	2142
2017 Q4	$52K	Hold	68	–	–	﹤0.01%	2100
2017 Q3	$17K	Hold	68	–	–	﹤0.01%	2133
2017 Q2	$15K	Hold	68	–	–	﹤0.01%	2091
2017 Q1	$24K	Hold	68	–	–	﹤0.01%	1961
2016 Q4	$41K	Sell	68 -7	-9%	-$7.4K	﹤0.01%	1830
2016 Q3	$86K	Hold	75	–	–	﹤0.01%	1751
2016 Q2	$80K	Hold	75	–	–	﹤0.01%	1614
2016 Q1	$94K	Hold	75	–	–	﹤0.01%	1915
2015 Q4	$183K	Sell	75 -4	-5%	-$6.14K	﹤0.01%	1770
2015 Q3	$91K	Sell	79 -21	-21%	-$24.3K	﹤0.01%	1739
2015 Q2	$100K	Buy	+100	New	+$108K	﹤0.01%	1421

Other funds holding NBSE

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

GBA

Garrison Bradford & Associates New York $88.4M AUM 15.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

HighTower Advisors's NBSE Position: Q4 2018 in Review

HighTower Advisors sold out of NeuBase Therapeutics, Inc. Common Stock (NBSE) in Q4 2018, closing a stake of 43 shares — an estimated $3K sold.

HighTower Advisors first reported a position in NBSE in Q2 2015 and held it in 14 quarters. The position peaked at $183K in Q4 2015. 24 funds tracked by Wall St. Rank hold NBSE as of Q4 2018.

HighTower Advisors reported no remaining NeuBase Therapeutics, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
HighTower Advisors sold 43 NeuBase Therapeutics, Inc. Common Stock shares in Q4 2018, an estimated $3K.
HighTower Advisors first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q2 2015 and held it in 14 quarters.
HighTower Advisors's NeuBase Therapeutics, Inc. Common Stock position peaked at $183K in Q4 2015.
24 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q4 2018.

Based on HighTower Advisors's 13F filing for Q4 2018, filed 14 Feb 2019.